Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645198 | 1.00 | HTT (0.40) | HTTALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL605762 | 0.85 | ALDH1A1 (0.39) | HTTALDH1A1MAPK1HSD17B1HSD17B2 | |
| SCHEMBL607945 | 0.85 | HSD17B10 (0.44) | HTTALDH1A1HPGDMAPK1HSD17B1 | |
| SCHEMBL5622209 | 0.85 | HTT (0.40) | HTTALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL31726498 | 0.84 | KDM4E (0.42) | HTTALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL27927680 | 0.83 | HSD17B10 (0.43) | HTTALDH1A1HPGDMAPK1HSD17B1 | |
| SCHEMBL2831221 | 0.83 | KDM4E (0.45) | ALDH1A1HPGDHSD17B1HSD17B2NR1H2 | |
| SCHEMBL3337229 | 0.83 | ROCK2 (0.38) | HTTALDH1A1HPGDHSD17B1HSD17B2 | |
| SCHEMBL3878770 | 0.82 | ITGB1 (0.36) | HSD17B1HSD17B2NR1H2NR1H3TSHR | |
| Potassium Ion SCHEMBL31265349 | 0.81 | CA1 (0.42) | HTTMAPK1HSD17B1HSD17B2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635494-A2 | AMIDO HETEROAROMATIC COMPOUNDS | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4514782-B1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-12291524-B2 | Amido heteroaromatic compounds | ASTRAZENECA AB (SE) | 2025-05-06 | — | — | US | disclosed |
| EP-4514782-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | Astrazeneca AB (SE) | 2025-03-05 | — | — | EP | disclosed |
| US-20250011311-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2025-01-09 | — | — | US | disclosed |
| WO-2023222850-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2023222850-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-8802895-B2 | Amide derivatives of benzene-sulfonanilide, pharmaceutical composition thereof and method for cancer treatment using the same | CLEVELAND STATE UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802895-B2 | Amide derivatives of benzene-sulfonanilide, pharmaceutical composition thereof and method for cancer treatment using the same | CLEVELAND STATE UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120095092-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | CLEVELAND STATE UNIVERSITY | 2012-04-19 | — | — | US | disclosed |
| US-20120095092-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | CLEVELAND STATE UNIVERSITY | 2012-04-19 | — | — | US | disclosed |
| EP-0298020-B1 | USE OF AN EPOXIDATION REAGENT, AND PROCESS FOR THE PREPARATION OF 5-ALPHA (10-ALPHA) EPOXY-DELTA 9(11) STEROIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-06-24 | — | — | EP | disclosed |
| EP-0298020-A1 | Use of an epoxidation reagent, and process for the preparation of 5-alpha (10-alpha) epoxy-delta 9(11) steroids | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291524-B2 | Amido heteroaromatic compounds | CYP7A1, SLC10A1, CYP11B2 | HTT 455/4885ALDH1A1 299/4885CYP3A4 35/4885 |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | HTT 455/4885ALDH1A1 299/4885CYP3A4 35/4885 |
| US-20120095092-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | RB1, BCR, NRAS | HTT 3907/4885ALDH1A1 639/4885CYP3A4 96/4885 |
| US-20250011311-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | HTT 455/4885ALDH1A1 299/4885CYP3A4 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.